Keytruda (pembrolizumab)

pCPA File Number: 21928
Negotiation Status:
Under consideration for negotiation
Indication(s):
Keytruda, in combination with Lenvima, for the treatment of adult patients with advanced or metastatic renal cell carcinoma (RCC) with no prior systemic therapy for metastatic RCC
Sponsor/Manufacturer:
Merck Canada Inc.
CADTH Project Number:
PC0268
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable